In an oral presentation today at the New York Academy of Sciences' Emerging Approaches to Cancer Immunotherapy conference, John Hunter, Ph.D., Site Head and Vice President of Antibody R&D at Compugen USA, Inc., a wholly owned subsidiary of Compugen Ltd. (NASDAQ: CGEN), presented results for CGEN-15029, the lead internal program in the Company's immuno-oncology therapeutics pipeline.